Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

115.79 -0.28 (-0.24%)
Official Closing Price Updated: 7:00 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,809,315
Open 115.15
Bid (Size) 114.63 (100)
Ask (Size) 116.52 (100)
Prev. Close 116.07
Today's Range 113.82 - 116.36
52wk Range 73.31 - 125.14
Shares Outstanding 2,531,374,696
Dividend Yield 2.94%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
On March 6, 2026, Moderna, Inc. (NASDAQ: MRNA) remains the centerpiece of biotech conversations following a staggering 14% surge in its share price earlier this week. For a company that became a... 
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies ↗
Merck can help stabilize investors' portfolios, whereas ImmunityBio would be a source of volatility. 
Via The Motley Fool

Performance

YTD
+8.8%
+8.8%
1 Month
-2.1%
-2.1%
3 Month
+16.1%
+16.1%
6 Month
+36.7%
+36.7%
1 Year
+23.2%
+23.2%

More News

Read More
News headline image
Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era
Via Finterra
Topics Intellectual Property
News headline image
ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth
Via MarketMinute
Topics Earnings Economy
News headline image
2 High-Flying Stocks With More Upside to Buy and Hold ↗
Via The Motley Fool
Topics Artificial Intelligence Supply Chain
News headline image
IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions ↗
Via Stocktwits
Topics Earnings Supply Chain
News headline image
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
USDA Deploys $100 Million 'Screwworm Challenge' to Safeguard U.S. Livestock and Dairy Frontier
Via MarketMinute
Topics Economy
News headline image
IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
From Merck & Co., Inc
Via Business Wire
News headline image
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
From Merck & Co., Inc.
Via Business Wire
News headline image
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗
Via The Motley Fool
Topics Lawsuit
News headline image
Big Tech’s Heavy Lifting: S&P 500 Q4 Earnings Surpass 8% Growth Amid AI Capex Anxiety
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Industrial Renaissance: Sector Surges 27% in Q4 2025 as Healthcare and Consumer Discretionary Lag
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire
News headline image
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results
Via MarketMinute
Topics Intellectual Property
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
United Therapeutics (UTHR) Deep Dive: Strong Q4 and the ‘Inhalation Evolution’
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance
Via MarketMinute
Topics Intellectual Property
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
Via MarketMinute
Topics Intellectual Property
News headline image
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
From Merck & Co., Inc.
Via Business Wire

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 115.79
When was Merck & Co last traded?
The last trade of Merck & Co was at 03/06/26 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 293.11B
How many shares of Merck & Co are outstanding?
Merck & Co has 293B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.